Among the MMR-deficient cases, the PLS group revealed significantly higher numbers of CD8+ T lymphocytes (p = 0.028) and peritumoral PD-L1+ immune cells (p = 0.009), and a tendency for higher numbers of peritumoral PD-1+ immune cells (p = 0.185) and PD-L1+ tumor cells (p = 0.093), compared to sporadic cancer with MLH1 methylation cases (Figure 2). The gene discussed is MRC1; the disease is neoplasm.